nexagon
Nucleic acidexperimental
Clinical trial activity
10 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00654550)
Timeline
Indications
Mechanism of action
- Gap junction alpha-1 proteinINHIBITOR
GJA1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nexagon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05966493 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2023 | Amber Ophthalmics, Inc. |
| NCT04081103 | Phase 2 | Oct 31, 2019 | Eyevance, Ocunexus |
| NCT01490879 | Phase 2 | Jul 1, 2012 | Ocunexus, University of Arizona |
| NCT01165450 | Phase 2 | Nov 1, 2011 | Food and Drug Administration, University of California, San Francisco |
| NCT01199588 | Phase 2 | May 1, 2011 | Ocunexus, University of Pennsylvania |
| NCT00820703 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2009 | Ocunexus |
| NCT00821561 | Phase 2 | Mar 1, 2009 | Ocunexus |
| NCT00820196 | Phase 2 | Mar 1, 2009 | Ocunexus |
| NCT00736593 | Phase 1 | Sep 1, 2008 | Auckland Clinical Studies, Ocunexus |
| NCT00654550 | Phase 1 | Apr 1, 2008 | Auckland Eye, Ocunexus |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ocunexus | For profit | 8 | 8 | 2 | 2008 |
| Amber Ophthalmics, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Auckland Clinical Studies | For profit | 1 | 0 | 1 | 2008 |
| Auckland Eye | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Eyevance | For profit | 1 | 0 | 1 | 2019 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2011 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2011 |
9 organizations
Page 1 / 1